Edgar Filing: CELL THERAPEUTICS INC - Form 4

CELL THER Form 4 December 12	APEUTICS INC								
	Л						PPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							3235-0287		
Check thi if no long subject to Section 1 Form 4 o	6.	OF CHANGES IN SECU	N BENEFIC RITIES	CIAL OW	NERSHIP OF	Expires: Estimated a burden hou response	rs per		
Form 5 obligation may cont <i>See</i> Instru 1(b).	$\frac{1}{1}$ Section $17(a)$ of	to Section 16(a) of t he Public Utility Ho (h) of the Investmen	lding Com	pany Act o	f 1935 or Section				
(Print or Type F	Responses)								
1. Name and A SINGER JA	ddress of Reporting Persor CK W	* 2. Issuer Name an Symbol CELL THERA		Ū.	5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (Middle)		3. Date of Earliest Transaction			(Check all applicable)			
			h/Day/Year) 1/2006			X Director 10% Owner X Officer (give title Other (specify below) below) EVP, Chief Medical Officer			
(Street) 4. If Amer Filed(Mon			Date Original ar)		 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
SEATTLE,	WA 98119				Person	fore than One Ke	eporting		
(City)	(State) (Zip)	Table I - Non	-Derivative S	ecurities Acc	quired, Disposed of	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date 2A. (Month/Day/Year) Exe any (Mo	cution Date, if Transac Code nth/Day/Year) (Instr. 8	ution(A) or Dis (D) (Instr. 3, 4)	sposed of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	12/11/2006	S <u>(1)</u>	1,600	D \$ 1.92	455,490	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: CELL THERAPEUTICS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
SINGER JACK W 501 ELLIOTT AVENUE WEST SUITE 400 SEATTLE, WA 98119	Х		EVP, Chie Medical Officer	ef			
Signatures							
Louis A. Bianco, Attorney-in-fact for Singer	12/12/2006						
**Signature of Reporting Person		Date					
Evenlay attack of Daam							

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Proceeds from the sale were used to cover taxes related to the vesting of restricted stock on December 11, 2006.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.